{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:52:56Z","timestamp":1781880776299,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41401-025-01744-y","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T08:27:17Z","timestamp":1772440037000},"page":"1917-1930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chloroethylnitrosourea analogue HJ03 overcomes temozolomide resistance of glioblastoma in mice through induction of ferroptosis and apoptosis"],"prefix":"10.1038","volume":"47","author":[{"given":"Heng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-fan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-zhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-dong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-min","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"1744_CR1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s12031-020-01542-7","volume":"70","author":"S Hosseindoost","year":"2020","unstructured":"Hosseindoost S, Hashemizadeh S, Gharaylou Z, Dehpour AR, Javadi SAH, Arjmand B, et al. \u03b22-adrenergic receptor stimulation upregulates Cx43 expression on glioblastoma multiforme and olfactory ensheathing cells. J Mol Neurosci. 2020;70:1451\u201360.","journal-title":"J Mol Neurosci"},{"key":"1744_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231\u201351.","journal-title":"Neuro Oncol"},{"key":"1744_CR3","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1093\/neuonc\/noac133","volume":"24","author":"K Smith","year":"2022","unstructured":"Smith K, Nakaji P, Thomas T, Pinnaduwage D, Wallstrom G, Choi M, et al. Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: results from a prospective trial. Neuro Oncol. 2022;24:S4\u2013s15.","journal-title":"Neuro Oncol"},{"key":"1744_CR4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00381-017-3381-6","volume":"33","author":"S Gupta","year":"2017","unstructured":"Gupta S, Mallick S, Benson R, Haresh KP, Julka PK, Rath GK. Extent of surgical resection and adjuvant temozolomide improves survival in pediatric GBM: a single center experience. Childs Nerv Syst. 2017;33:951\u20136.","journal-title":"Childs Nerv Syst"},{"key":"1744_CR5","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1158\/1078-0432.CCR-07-1719","volume":"14","author":"JN Sarkaria","year":"2008","unstructured":"Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14:2900\u20138.","journal-title":"Clin Cancer Res"},{"key":"1744_CR6","first-page":"639","volume":"24","author":"YD Zhang","year":"2014","unstructured":"Zhang YD, Dai RY, Chen Z, Zhang YH, He XZ, Zhou J. Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review. Turk Neurosurg. 2014;24:639\u201345.","journal-title":"Turk Neurosurg"},{"key":"1744_CR7","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1200\/JCO.19.02983","volume":"38","author":"EH Bell","year":"2020","unstructured":"Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, et al. Comprehensive genomic analysis in NRG oncology\/RTOG 9802: a Phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol. 2020;38:3407\u201317.","journal-title":"J Clin Oncol"},{"key":"1744_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1124\/mol.107.044743","volume":"74","author":"S Caporali","year":"2008","unstructured":"Caporali S, Levati L, Starace G, Ragone G, Bonmassar E, Alvino E, et al. AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol Pharmacol. 2008;74:173\u201383.","journal-title":"Mol Pharmacol"},{"key":"1744_CR9","doi-asserted-by":"crossref","unstructured":"Strobel H, Baisch T, Fitzel R, Schilberg K, Siegelin MD, Karpel-Massler G, et al. Temozolomide and other alkylating agents in glioblastoma therapy. Biomedicines. 2019;7:69.","DOI":"10.3390\/biomedicines7030069"},{"key":"1744_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188616","volume":"1876","author":"MS Tomar","year":"2021","unstructured":"Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer. 2021;1876:188616.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1744_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.388","volume":"4","author":"CH Fan","year":"2013","unstructured":"Fan CH, Liu WL, Cao H, Wen C, Chen L, Jiang G. O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis. 2013;4:e876.","journal-title":"Cell Death Dis"},{"key":"1744_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1172\/JCI59334","volume":"122","author":"S Agnihotri","year":"2012","unstructured":"Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, et al. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest. 2012;122:253\u201366.","journal-title":"J Clin Invest."},{"key":"1744_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev.bi.57.070188.001025","volume":"57","author":"T Lindahl","year":"1988","unstructured":"Lindahl T, Sedgwick B, Sekiguchi M, Nakabeppu Y. Regulation and expression of the adaptive response to alkylating agents. Annu Rev Biochem. 1988;57:133\u201357.","journal-title":"Annu Rev Biochem"},{"key":"1744_CR14","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1021\/tx700271j","volume":"20","author":"R Coulter","year":"2007","unstructured":"Coulter R, Blandino M, Tomlinson JM, Pauly GT, Krajewska M, Moschel RC, et al. Differences in the rate of repair of O6-alkylguanines in different sequence contexts by O6-alkylguanine-DNA alkyltransferase. Chem Res Toxicol. 2007;20:1966\u201371.","journal-title":"Chem Res Toxicol"},{"key":"1744_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4103\/glioma.glioma_3_19","volume":"2","author":"P Woo","year":"2019","unstructured":"Woo P, Li Y, Chan AHY, Ng S, Loong H, Chan D, et al. A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O\u20116\u2011methylguanine\u2011DNA methyltransferase. Glioma. 2019;2:68\u201382.","journal-title":"Glioma"},{"key":"1744_CR16","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-06-2149","volume":"13","author":"DP Cahill","year":"2007","unstructured":"Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007;13:2038\u201345.","journal-title":"Clin Cancer Res"},{"key":"1744_CR17","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-06-0127","volume":"66","author":"C Hunter","year":"2006","unstructured":"Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006;66:3987\u201391.","journal-title":"Cancer Res"},{"key":"1744_CR18","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/ijc.23219","volume":"122","author":"D Wiewrodt","year":"2008","unstructured":"Wiewrodt D, Nagel G, Dreim\u00fcller N, Hundsberger T, Perneczky A, Kaina B. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Int J Cancer. 2008;122:1391\u20139.","journal-title":"Int J Cancer"},{"key":"1744_CR19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","volume":"393","author":"U Herrlinger","year":"2019","unstructured":"Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019;393:678\u201388.","journal-title":"Lancet"},{"key":"1744_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbcan.2017.01.004","volume":"1868","author":"T Nikolova","year":"2017","unstructured":"Nikolova T, Roos WP, Kr\u00e4mer OH, Strik HM, Kaina B. Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling. Biochim Biophys Acta Rev Cancer. 2017;1868:29\u201339.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1744_CR21","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1200\/JCO.2008.19.2195","volume":"27","author":"M Glas","year":"2009","unstructured":"Glas M, Happold C, Rieger J, Wiewrodt D, Bahr O, Steinbach JP, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol. 2009;27:1257\u201361.","journal-title":"J Clin Oncol"},{"key":"1744_CR22","doi-asserted-by":"publisher","first-page":"7120","DOI":"10.1021\/jm401121k","volume":"56","author":"D Pletsas","year":"2013","unstructured":"Pletsas D, Garelnabi EA, Li L, Phillips RM, Wheelhouse RT. Synthesis and quantitative structure-activity relationship of imidazotetrazine prodrugs with activity independent of O6-methylguanine-DNA-methyltransferase, DNA mismatch repair, and p53. J Med Chem. 2013;56:7120\u201332.","journal-title":"J Med Chem"},{"key":"1744_CR23","unstructured":"Xi B, Zheng D, Wang T, Liu S, Yang H, Han J, inventors. A chloroethyl nitrosourea compound containing aryl, and its preparation method and application. Chinese patent CN117486761A. 2024 Feb 02."},{"key":"1744_CR24","doi-asserted-by":"publisher","first-page":"15563","DOI":"10.1021\/jacs.6b10354","volume":"138","author":"AR Healy","year":"2016","unstructured":"Healy AR, Nikolayevskiy H, Patel JR, Crawford JM, Herzon SB. A mechanistic model for colibactin-induced genotoxicity. J Am Chem Soc. 2016;138:15563\u201370.","journal-title":"J Am Chem Soc"},{"key":"1744_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104353","volume":"86","author":"TT Liu","year":"2022","unstructured":"Liu TT, Yang H, Zhuo FF, Yang Z, Zhao MM, Guo Q, et al. Atypical E3 ligase ZFP91 promotes small-molecule-induced E2F2 transcription factor degradation for cancer therapy. EBioMedicine. 2022;86:104353.","journal-title":"EBioMedicine"},{"key":"1744_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jare.2020.07.007","volume":"28","author":"Y Wang","year":"2020","unstructured":"Wang Y, Quan F, Cao Q, Lin Y, Yue C, Bi R, et al. Quercetin alleviates acute kidney injury by inhibiting ferroptosis. J Adv Res. 2020;28:231\u201343.","journal-title":"J Adv Res"},{"key":"1744_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41420-024-01869-9","volume":"10","author":"L Contreras","year":"2024","unstructured":"Contreras L, Garc\u00eda-Gaipo L, Casar B, Gandarillas A. DNA damage signalling histone H2AX is required for tumour growth. Cell Death Discov. 2024;10:99.","journal-title":"Cell Death Discov"},{"key":"1744_CR28","doi-asserted-by":"crossref","unstructured":"Owen N, Minko IG, Moellmer SA, Cammann SK, Lloyd RS, McCullough AK. Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells. Proc Natl Acad Sci USA. 2021;118:e2016833118.","DOI":"10.1073\/pnas.2016833118"},{"key":"1744_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023;8:217.","journal-title":"Signal Transduct Target Ther"},{"key":"1744_CR30","first-page":"513","volume":"19","author":"R Ortiz","year":"2021","unstructured":"Ortiz R, Perazzoli G, Cabeza L, Jim\u00e9nez-Luna C, Luque R, Prados J, et al. Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications. Curr Neuropharmacol. 2021;19:513\u201337.","journal-title":"Curr Neuropharmacol"},{"key":"1744_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1021\/acschembio.2c00022","volume":"17","author":"RL Svec","year":"2022","unstructured":"Svec RL, McKee SA, Berry MR, Kelly AM, Fan TM, Hergenrother PJ. Novel imidazotetrazine evades known resistance mechanisms and is effective against temozolomide-resistant brain cancer in cell culture. ACS Chem Biol. 2022;17:299\u2013313.","journal-title":"ACS Chem Biol"},{"key":"1744_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111810","volume":"141","author":"S Liu","year":"2021","unstructured":"Liu S, Shi W, Zhao Q, Zheng Z, Liu Z, Meng L, et al. Progress and prospect in tumor treating fields treatment of glioblastoma. Biomed Pharmacother. 2021;141:111810.","journal-title":"Biomed Pharmacother"},{"key":"1744_CR33","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997\u20131003.","journal-title":"N Engl J Med"},{"key":"1744_CR34","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3390\/cells9071665","volume":"9","author":"A Carusillo","year":"2020","unstructured":"Carusillo A, Mussolino C. DNA damage: from threat to treatment. Cells. 2020;9:1665.","journal-title":"Cells"},{"key":"1744_CR35","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.molcel.2022.03.022","volume":"82","author":"D Liang","year":"2022","unstructured":"Liang D, Minikes AM, Jiang X. Ferroptosis at the intersection of lipid metabolism and cellular signaling. Mol Cell. 2022;82:2215\u201327.","journal-title":"Mol Cell"},{"key":"1744_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2024.101254","volume":"12","author":"Z Su","year":"2024","unstructured":"Su Z, Liu Y, Wang L, Gu W. Regulation of SLC7A11 as an unconventional checkpoint in tumorigenesis through ferroptosis. Genes Dis. 2024;12:101254.","journal-title":"Genes Dis"},{"key":"1744_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.944452","volume":"13","author":"AB Mahmoud","year":"2022","unstructured":"Mahmoud AB, Ajina R, Aref S, Darwish M, Alsayb M, Taher M, et al. Advances in immunotherapy for glioblastoma multiforme. Front Immunol. 2022;13:944452.","journal-title":"Front Immunol"},{"key":"1744_CR38","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1158\/1078-0432.CCR-13-3229","volume":"21","author":"MA Morgan","year":"2015","unstructured":"Morgan MA, Lawrence TS. Molecular pathways: overcoming radiation resistance by targeting DNA damage response pathways. Clin Cancer Res. 2015;21:2898\u2013904.","journal-title":"Clin Cancer Res"},{"key":"1744_CR39","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/kjm2.12375","volume":"37","author":"RA Lin","year":"2021","unstructured":"Lin RA, Lin JK, Lin SY. Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. Kaohsiung J Med Sci. 2021;37:448\u201358.","journal-title":"Kaohsiung J Med Sci"},{"key":"1744_CR40","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","volume":"41","author":"L Rong","year":"2022","unstructured":"Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res. 2022;41:142.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01744-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01744-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01744-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:04:43Z","timestamp":1781877883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01744-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1744"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01744-y","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u00a0Ting Wang is an employee of Guangzhou KemRocMed Co., Ltd., Guangzhou, China; Li-zhi Zhu is an employee of Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., Shenzhen, China. Both authors declare no conflicts of interest related to this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}